Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Zhang

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Cureus|October 26, 2017
Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual EtiologiesJunior Kalambay, Haider Ghazanfar, Karen A Martes Pena, et al.
Plos One|August 15, 2019
(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cellsLimor Goren, George Zhang, Susmita Kaushik, et al.
Thrombosis and Haemostasis|May 26, 2012
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsHamim Zahir, Nobuko Matsushima, Abdel-Baset Halim, et al.
Heart (British Cardiac Society)|July 10, 2017
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolismAlexander G Vandell, Joseph Walker, Karen S Brown, et al.
Thrombosis and Haemostasis|February 3, 2017
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonistsMarcello Di Nisio, Gary Raskob, Harry R Büller, et al.
Molecular Cancer Therapeutics|May 2, 2022
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple MutationsYong Du, Yongfeng Chen, Yuxia Wang, et al.
Clinical Pharmacokinetics|May 18, 2017
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy AdultsKenneth Duchin, Anil Duggal, George J Atiee, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2018
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy SubjectsAlexander G Vandell, Satoshi Inoue, Justin Dennie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 18, 2021
Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static ModelDiane Ramsden, Elke S Perloff, Andrea Whitcher-Johnstone, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2024
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver functionJing Zhou, Hong Zhang, Hong Chen, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Cureus|October 26, 2017
Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual EtiologiesJunior Kalambay, Haider Ghazanfar, Karen A Martes Pena, et al.
Plos One|August 15, 2019
(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cellsLimor Goren, George Zhang, Susmita Kaushik, et al.
Thrombosis and Haemostasis|May 26, 2012
Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsHamim Zahir, Nobuko Matsushima, Abdel-Baset Halim, et al.
Heart (British Cardiac Society)|July 10, 2017
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolismAlexander G Vandell, Joseph Walker, Karen S Brown, et al.
Thrombosis and Haemostasis|February 3, 2017
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonistsMarcello Di Nisio, Gary Raskob, Harry R Büller, et al.
Molecular Cancer Therapeutics|May 2, 2022
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple MutationsYong Du, Yongfeng Chen, Yuxia Wang, et al.
Clinical Pharmacokinetics|May 18, 2017
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy AdultsKenneth Duchin, Anil Duggal, George J Atiee, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2018
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy SubjectsAlexander G Vandell, Satoshi Inoue, Justin Dennie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 18, 2021
Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static ModelDiane Ramsden, Elke S Perloff, Andrea Whitcher-Johnstone, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2024
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver functionJing Zhou, Hong Zhang, Hong Chen, et al.
Pageof 8